首页> 外文期刊>Journal of clinical psychopharmacology >Omega-3 Fatty Acids, Depressive Symptoms, and Cognitive Performance in Patients With Coronary Artery Disease: Analyses From a Randomized, Double-Blind, Placebo-Controlled Trial
【24h】

Omega-3 Fatty Acids, Depressive Symptoms, and Cognitive Performance in Patients With Coronary Artery Disease: Analyses From a Randomized, Double-Blind, Placebo-Controlled Trial

机译:冠状动脉疾病患者的Omega-3脂肪酸,抑郁症状和认知能力:一项来自随机,双盲,安慰剂对照试验的分析

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

This trial investigated the efficacy of omega-3 polyunsaturated fatty acid (n-3 PUFA) treatment for improving depressive symptoms and cognitive performance in patients with coronary artery disease (CAD) participating in cardiac rehabilitation. Patients with CAD aged 45 to 80 years were randomized to receive either 1.9-g/d n-3 PUFA treatment or placebo for 12 weeks. Depressive symptoms were measured using the Hamilton Depression Rating Scale (HAM-D, primary outcome) and the Beck Depression Inventory II (BDI-II). Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, criteria were used to identify a depressive episode at baseline. Cognitive performance was measured using a standardized battery for vascular cognitive impairment. In 92 patients (age, 61.7 +/- 8.7 y; 76% male, 40% depressed; HAM-D, 6.9 +/- 5.9; BDI-II, 12.3 +/- 10.9; n = 45 n-3 PUFA, n = 47 placebo), depression decreased (HAM-D, F-3,F-91 = 2.71 and P = 0.049; BDI-II, F-3,F-91 = 6.24 and P < 0.01), and cognitive performance improved (attention/processing speed, F-1,F-91 = 5.57, P = 0.02; executive function, F-1,F-91 = 14.64, P < 0.01; visuospatial memory, F-1,F-91 = 4.01, P = 0.04) over cardiac rehabilitation. Omega-3 PUFA treatment increased plasma eicosapentaenoic acid (F-1,F-29 = 33.29, P < 0.01) and docosahexaenoic acid (F-1,F-29 = 15.29, P < 0.01) concentrations but did not reduce HAM-D (F-3,F-91 = 1.59, P = 0.20) or BDI-II (F-3,F-91 = 0.46, P = 0.50) scores compared with placebo. Treatment did not improve cognitive performance; however, n-3 PUFAs significantly increased verbal memory compared with placebo in a subgroup of nondepressed patients (F-1,F-54 = 4.16, P = 0.04). This trial suggests that n-3 PUFAs do not improve depressive and associated cognitive symptoms in those with CAD. The possible benefits of n-3 PUFAs for verbal memory may warrant investigation in well-powered studies.
机译:该试验研究了omega-3多不饱和脂肪酸(n-3 PUFA)治疗对参与心脏康复的冠心病(CAD)患者的抑郁症状和认知功能的改善作用。 45至80岁的CAD患者被随机分配接受1.9 g / d n-3 PUFA治疗或安慰剂治疗12周。使用汉密尔顿抑郁量表(HAM-D,主要结局)和贝克抑郁量表II(BDI-II)测量抑郁症状。 《精神疾病诊断和统计手册》,第四版,使用标准确定基线时的抑郁发作。使用标准化电池测量血管性认知障碍的认知能力。在92位患者中(年龄61.7 +/- 8.7岁; 76%男性,40%抑郁; HAM-D,6.9 +/- 5.9; BDI-II,12.3 +/- 10.9; n = 45 n-3 PUFA,n = 47个安慰剂),抑郁症减轻(HAM-D,F-3,F-91 = 2.71和P = 0.049; BDI-II,F-3,F-91 = 6.24和P <0.01),认知能力得到改善(注意/处理速度,F-1,F-91 = 5.57,P = 0.02;执行功能,F-1,F-91 = 14.64,P <0.01;视觉空间记忆,F-1,F-91 = 4.01,P = 0.04)。 Omega-3 PUFA处理可增加血浆二十碳五烯酸(F-1,F-29 = 33.29,P <0.01)和二十二碳六烯酸(F-1,F-29 = 15.29,P <0.01)的浓度,但并未降低HAM-D (F-3,F-91 = 1.59,P = 0.20)或BDI-II(F-3,F-91 = 0.46,P = 0.50)得分与安慰剂相比。治疗没有改善认知能力;然而,与安慰剂相比,n-3 PUFAs在非抑郁患者亚组中的言语记忆显着增加(F-1,F-54 = 4.16,P = 0.04)。该试验表明,n-3 PUFAs不能改善CAD患者的抑郁和相关的认知症状。 n-3 PUFA对于口头记忆的可能益处可能需要在功能强大的研究中进行研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号